Loading
companiesCompany
Arcus Biosciences
Arcus Biosciences is a United States-based biotechnology company running 4 late-stage cancer trials of Domvanalimab and Quemliclustat in gastric & gastro-oesophageal junction cancer, renal cell carcinoma and pancreatic ductal adenocarcinoma.
Also called: Arcus Biosciences, Inc.
Overview
Arcus Biosciences, based in Hayward, the United States, is a biotechnology company. Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small-molecule and antibody combination therapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Domvanalimab and Quemliclustat in gastric & gastro-oesophageal junction cancer, renal cell carcinoma, pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT07011719 (Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma), plans to enrol 720 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Hayward, US
Scorecard
All companies#159of 1244 companies, score 37
- approved products +6
- phase 3 +6
- targets +2
- modalities +4
- regions +1
- registry trials +18
1 approved, 2 in phase 3, 0 earlier, 1 targets, 83 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2015
Phase 3monoclonal antibody
Domvanalimab is an experimental monoclonal antibody from Gilead Sciences in phase 3 trials for non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
Quemliclustat is an experimental investigational agent whose form is not stated in the registry from Arcus Biosciences in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, with its target not yet stated publicly.
ApprovedAnti-PD-1 monoclonal antibody, intravenous
Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab.
Similar pages
- TrialStudy With Various Immunotherapy Treatments in Participants With Lung Cancer
Shares Quemliclustat, Domvanalimab, Zimberelimab, Non-small-cell lung cancer.
- TrialStudy of Novel Treatment Combinations in Patients With Lung Cancer
Shares Domvanalimab, Zimberelimab, Non-small-cell lung cancer.
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Domvanalimab, Zimberelimab.
- TrialDomvanalimab and Zimberelimab in Advanced Liver Cancers
Shares Domvanalimab, Zimberelimab.
- TrialA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Shares Domvanalimab, Non-small-cell lung cancer.
- TrialZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Shares Domvanalimab, Non-small-cell lung cancer.
- CompanyGilead Sciences (incl. Kite)
Shares Quemliclustat, A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies, Domvanalimab.
cancers
drugs
Phase 3monoclonal antibody
Phase 3not stated (registered as a drug or biological on ClinicalTrials.gov)
ApprovedAnti-PD-1 monoclonal antibody, intravenous
companies
trials
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation forA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerStudy of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma